{
    "download_date": [
        "ClinicalTrials.gov processed this data on May 09, 2023"
    ],
    "link_text": [
        "Link to the current ClinicalTrials.gov record."
    ],
    "url": [
        "https://clinicaltrials.gov/show/NCT05382364",
        "http://merckoncologyclinicaltrials.com"
    ],
    "org_study_id": [
        "7119-002"
    ],
    "secondary_id": [
        "MK-7119-002"
    ],
    "nct_id": [
        "NCT05382364"
    ],
    "brief_title": [
        "Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)"
    ],
    "official_title": [
        "A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer"
    ],
    "lead_sponsor": [],
    "source": [
        "Merck Sharp & Dohme LLC"
    ],
    "has_dmc": [
        "No"
    ],
    "is_fda_regulated_drug": [
        "Yes"
    ],
    "is_fda_regulated_device": [
        "No"
    ],
    "is_us_export": [
        "Yes"
    ],
    "textblock": [
        "The primary purpose of this study is to characterize the safety and tolerability of tucatinib\r\n      (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive\r\n      (HER2+) advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma (GEC),\r\n      and colorectal cancer."
    ],
    "overall_status": [
        "Active, not recruiting"
    ],
    "type": [
        "Actual",
        "Anticipated",
        "Anticipated",
        "Anticipated",
        "Actual",
        "Actual"
    ],
    "start_date": [
        "June 29, 2022"
    ],
    "completion_date": [
        "December 29, 2025"
    ],
    "primary_completion_date": [
        "December 29, 2023"
    ],
    "phase": [
        "Phase 1"
    ],
    "study_type": [
        "Interventional"
    ],
    "has_expanded_access": [
        "No"
    ],
    "allocation": [],
    "intervention_model": [
        "Single Group Assignment"
    ],
    "primary_purpose": [
        "Treatment"
    ],
    "masking": [
        "None (Open Label)"
    ],
    "measure": [
        "Percentage of participants with \u22651 adverse event (AE)",
        "Percentage of participants discontinuing from study therapy due to AE",
        "Maximum plasma concentration (Cmax) of first dose of tucatinib",
        "Time of maximum plasma concentration (Tmax) of first dose of tucatinib",
        "Area under the plasma concentration time curve from dosing to 12 hours postdose (AUC0-12) of first dose of tucatinib",
        "Apparent plasma half-life (t\u00bd) of first dose of tucatinib",
        "Apparent clearance (CL/F) of first dose of tucatinib",
        "Volume of distribution (Vz/F) of first dose of tucatinib",
        "Trough concentration (Ctrough) of tucatinib at steady state",
        "Accumulation ratio of tucatinib at steady state",
        "Cmax at steady state (Cmaxss) of tucatinib",
        "Tmax at steady state (Tmaxss) of tucatinib",
        "AUC0-12 at steady state (AUC0-12ss) of tucatinib",
        "t\u00bd of tucatinib at steady state",
        "CL/F at steady state (CL/Fss) of tucatinib",
        "Vz/F at steady state (Vz/Fss) of tucatinib",
        "Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)",
        "Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)"
    ],
    "time_frame": [
        "Up to approximately 19 months",
        "Up to approximately 18 months",
        "Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 1, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 1, Days 8 and 15: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Cycle 2, Day 1: predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose",
        "Up to approximately 19 months",
        "Up to approximately 19 months"
    ],
    "description": [
        "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
        "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
        "The Cmax of tucatinib will be determined after the first dose.",
        "The Tmax of tucatinib will be determined after the first dose.",
        "The AUC0-12 of tucatinib will be determined after the first dose.",
        "The t\u00bd of tucatinib will be determined after the first dose.",
        "The CL/F of tucatinib will be determined after the first dose.",
        "The Vz/F of tucatinib will be determined after the first dose.",
        "The Ctrough of tucatinib will be determined at steady state.",
        "The accumulation ratio of tucatinib will be determined at steady state.",
        "The Cmaxss of tucatinib will be determined at steady state.",
        "The Tmaxss of tucatinib will be determined at steady state.",
        "The AUC0-12ss of tucatinib will be determined at steady state.",
        "The t\u00bd of tucatinib will be determined at steady state.",
        "The CL/Fss of tucatinib will be determined at steady state.",
        "The Vz/Fss of tucatinib will be determined at steady state.",
        "ORR is defined as the percentage of participants who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR based on RECIST 1.1 will be presented.",
        "For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death.",
        "Chinese participants with HER2+ advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma, or colorectal cancer receive tucatinib 300 mg by mouth twice daily during 21-day cycles. Treatment continues until there is evidence of unacceptable toxicity or documented progression.",
        "Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.",
        "Merck Oncology Clinical Trials Information"
    ],
    "number_of_arms": [
        1.0
    ],
    "enrollment": [
        25.0
    ],
    "condition": [
        "Metastatic HER2+ Advanced Breast Cancer",
        "Breast Neoplasms",
        "Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)",
        "Colorectal Cancer"
    ],
    "arm_group_label": [
        "Tucatinib Treatment",
        "Tucatinib Treatment"
    ],
    "arm_group_type": [
        "Experimental"
    ],
    "intervention_type": [
        "Drug"
    ],
    "intervention_name": [
        "Tucatinib"
    ],
    "other_name": [
        "MK-7119"
    ],
    "criteria": [],
    "gender": [
        "All"
    ],
    "minimum_age": [
        "18 Years"
    ],
    "maximum_age": [],
    "healthy_volunteers": [
        "No"
    ],
    "last_name": [
        "Medical Director"
    ],
    "role": [
        "Study Director"
    ],
    "affiliation": [
        "Merck Sharp & Dohme LLC"
    ],
    "facility": [],
    "country": [
        "China"
    ],
    "verification_date": [
        "February 2023"
    ],
    "study_first_submitted": [
        "May 16, 2022"
    ],
    "study_first_submitted_qc": [
        "May 16, 2022"
    ],
    "study_first_posted": [
        "May 19, 2022"
    ],
    "last_update_submitted": [
        "February 21, 2023"
    ],
    "last_update_submitted_qc": [
        "February 21, 2023"
    ],
    "last_update_posted": [
        "February 22, 2023"
    ],
    "responsible_party_type": [
        "Sponsor"
    ],
    "mesh_term": [
        "Esophageal Neoplasms",
        "Tucatinib"
    ],
    "sharing_ipd": [
        "Yes"
    ],
    "ipd_description": [
        "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf"
    ],
    "ipd_url": [
        "http://engagezone.msd.com/ds_documentation.php"
    ]
}